Efficacy of lenalidomide combined with bortezomib and dexamethasone in the treatment of multiple myeloma
10.11958/20250356
- VernacularTitle:来那度胺联合硼替佐米和地塞米松治疗多发性骨髓瘤的疗效
- Author:
Lili XIANG
1
;
Qian WANG
1
;
Yanna MENG
1
;
Jie FU
1
;
Pu ZHANG
1
Author Information
1. 徐州市中心医院血液科(邮编 221000)
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
lenalidomide;
bortezomib;
dexamethasone;
HSP90 heat-shock proteins;
HMGB1 protein;
miR-28-5p;
tartrate resistant acid phosphatase 5b isoenzyme
- From:
Tianjin Medical Journal
2025;53(6):665-669
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of lenalidomide combined with bortezomib and dexamethasone in the treatment of multiple myeloma(MM)and their effects on heat shock protein 90(HSP90)mRNA,miR-28-5p,anti-tartrate acid phosphatase 5b(TRACP-5b)and high mobility group protein B1(HMGB1).Methods Eighty patients with newly diagnosed MM were selected and divided into the two-combination group(40 patients treated with bortezomib and dexamethasone)and the three-combination group(40 patients treated with bortezomib and dexamethasone combined with lenalidomide)according to the treatment modalities.Real-time fluorescence quantitative polymerase chain reaction was used to detect HSP90 mRNA and miR-28-5p levels.Enzyme-linked immunosorbent assay was used to detect TRACP-5b and HMGB1 levels.The clinical efficacy of the 2 groups was compared.Levels of HSP90 mRNA,miR-28-5p,TRACP-5b,HMGB1,the immune cell function,renal function indexes and the incidence of adverse reactions were compared before and after treatment.Results The total effective rate of the three-combination group was higher than that of the two-combination groups(92.50%vs.75.00%,P＜0.05).Compared with the pretreatment,the levels of HSP90 mRNA,TRACP-5b,blood creatinine(SCr),and urea nitrogen(BUN)decreased in the 2 groups after treatment,and which was lower in the three-combination group than that in the two-combination groups.The levels of miR-28-5p,HMGB1,CD4+,CD3+and CD4+/CD8+were elevated in the 2 groups,and the levels were higher in the three-combination group than those in the two-combination group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion Lenalidomide combined with bortezomib and dexamethasone is clinically effective,safe and reliable in the treatment of MM.
